MIMEDX GROUP, INC.MDXGEarnings & Financial Report
MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.
Revenue
$84.7M
Gross Profit
$71.7M
Operating Profit
$13.2M
Net Profit
$9.3M
Gross Margin
84.7%
Operating Margin
15.6%
Net Margin
10.9%
YoY Growth
18.2%
EPS
$0.06
MIMEDX GROUP, INC. Q1 FY2024 Financial Summary
MIMEDX GROUP, INC. reported revenue of $84.7M (up 18.2% YoY) for Q1 FY2024, with a net profit of $9.3M (up 285.9% YoY) (10.9% margin). Cost of goods sold was $13.0M, operating expenses totaled $58.5M.
Key Financial Metrics
| Total Revenue | $84.7M |
|---|---|
| Net Profit | $9.3M |
| Gross Margin | 84.7% |
| Operating Margin | 15.6% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
MIMEDX GROUP, INC. Q1 FY2024 revenue of $84.7M breaks down across 3 segments, led by Hospital Site Of Service at $43.8M (51.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Hospital Site Of Service | $43.8M | 51.7% |
| Private Office Site Of Service | $30.3M | 35.8% |
| Other Site Of Service | $10.6M | 12.5% |
MIMEDX GROUP, INC. Annual Revenue by Year
MIMEDX GROUP, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $418.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $418.6M |
| 2024 | $348.9M |
| 2023 | $321.5M |
| 2022 | $267.8M |
MIMEDX GROUP, INC. Quarterly Revenue & Net Profit History
MIMEDX GROUP, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $118.1M | +27.1% | $15.2M | 12.9% |
| Q3 FY2025 | $113.7M | +35.3% | $16.7M | 14.7% |
| Q2 FY2025 | $98.6M | +13.1% | $9.6M | 9.8% |
| Q1 FY2025 | $88.2M | +4.1% | $7.0M | 8.0% |
| Q4 FY2024 | $92.9M | +7.0% | $7.4M | 8.0% |
| Q3 FY2024 | $84.1M | +2.9% | $8.1M | 9.6% |
| Q2 FY2024 | $87.2M | +7.3% | $17.6M | 20.2% |
| Q1 FY2024 | $84.7M | +18.2% | $9.3M | 10.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84.7M | $87.2M | $84.1M | $92.9M | $88.2M | $98.6M | $113.7M | $118.1M |
| YoY Growth | 18.2% | 7.3% | 2.9% | 7.0% | 4.1% | 13.1% | 35.3% | 27.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $221.7M | $230.2M | $243.9M | $263.9M | $270.4M | $291.1M | $319.0M | $342.7M |
| Liabilities | $66.0M | $62.1M | $62.9M | $70.8M | $67.6M | $74.5M | $80.0M | $86.1M |
| Equity | $155.7M | $168.0M | $181.0M | $193.1M | $202.8M | $216.6M | $238.9M | $256.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $6.0M | $21.8M | $19.6M | $18.8M | $5.3M | $14.4M | $29.3M | $25.0M |